

Example of Nicotinamide's Failure to Act as an Antiviral In Vivo

Patient #1

Time	Viral Load
pretreatment	> 1,000,000 copies
1 week on therapy	765,000 copies
1 month on therapy	>1,000,000 copies

Explanation – this is the extent of available viral load data from the study which lead to the '552 patent application examples. This patient took 3 grams of nicotinamide per day for 2 months. The viral load is a measure of the amount of virus in 1 ml of patient blood. A patient on effective antiviral therapy will have a steady decrease in their viral load until it becomes undetectable [i.e. less than 50 copies per ml of blood].

Conclusion – while this is not conclusive scientific data, this early data from patient #1 lead to the impression that nicotinamide did not have a clear in vivo antiviral effect. While the one week result looked somewhat favorable, when viewed as a complete set the variations in the three time points are within the daily variations seen in this test in people not on antiviral therapy. Given the emerging data I was developing at this time on increases in plasma tryptophan, the focus of the study became the tryptophan results and further viral load measurements were not obtained on this patient or the other three patients in the patent examples.

EXHIBIT H